We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ:ADTX), in connection with the proposed merger of the Company with AiPharma Global Holdings LLC (“AiPharma”).  Under the terms of the share exchange agreement, the Company will first acquire 9.5% of the issued and outstanding equity interests in AiPharma in exchange for the issuance of approximately 4.8 million shares of common stock of Aditxt and a cash payment of $250,000.  Aditxt would then acquire the remaining 90.5% of the issued and outstanding equity interests in AiPharma in exchange for the issuance of approximately 39.9 million shares of common stock of Aditxt and a cash payment of $250,000 at a secondary closing.

WeissLaw LLP is investigating whether (i) Aditxt’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, and (ii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.